Skip to main content

Moleculin Biotech, Inc 8-K, filed Nov 16, 2026

Moleculin Biotech, Inc. (MBRX)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Moleculin Biotech, Inc filed this 8-K on November 16, 2026.

Moleculin Biotech, Inc. completed Part A treatment for all 90 patients in the Phase 2/3 MIRACLE trial, with comprehensive data on track for the first quarter of 2027. Third-quarter net loss was approximately $6.5 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits